Edison Investment Research - Pharmaceutical & healthcare - CASI Pharmaceuticals: We are initiating coverage on CASI Pharmaceuticals, which is focused on leveraging regulatory synergies between the US and China to quickly bring products to market. The regulatory environment in China is rapidly evolving and is actively encouraging the entry of foreign drugs. CASI intends to leverage this with a portfolio of three proprietary oncology drugs (licensed from Spectrum) and 30 ANDAs (bought from Sandoz and Laurus Labs). We arrive at an initial valuation of $754m or $8.06 per share.
ISIN: US14757U1097
Original Article: CASI Pharmaceuticals (CASI) - Riding the wave of Chinese reform